At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Closed Good Friday 04-17 16:00:00 EDT
69.98
+0.05
+0.07%
盘后66.00
-3.98-5.69%
19:55 EDT
High70.51
Low68.34
Vol1.24M
Open69.96
D1 Closing69.93
Amplitude3.11%
Mkt Cap3.21B
Tradable Cap2.19B
Total Shares45.86M
T/O85.92M
T/O Rate3.95%
Tradable Shares31.32M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Soleno Therapeutics Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.